FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

Go to full article published by the FDA.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.